Marvel Biosciences Corp. completed a non-brokered private placement, raising approximately $1.6 million by issuing over 10.6 million units at $0.15 each. The funds will support phase 1 clinical trials for its lead compound MB-204, a drug targeting neurological diseases like Parkinson's, autism, and Alzheimer's. Each unit includes a common share and a warrant to buy another share at $0.20, exercisable after 61 days for one year. The company aims to advance its drug redevelopment approach, focusing on synthetic derivatives of approved drugs to treat new indications with lower risk and cost.
Marvel Biosciences private placement news is given context by Pluang's health sector data. Of 100 health-sector US stocks on Pluang, 42 rose and 56 fell on September 30, 2026, at 04:11 WIB. Notable movers include HRTX at USD 0.31 with a 6.24% increase and a typical hold time of 35 days, SMMT at USD 16.36 up 5.68%, and REGN at USD 754.00 down 4.32%, with respective Pluang order activities noted.
GameStop's CEO Ryan Cohen and other executives have made significant insider purchases of millions of shares, showing strong confidence in the company's future despite recent stock price volatility. These buys were active decisions, not pre-scheduled...
Grass token briefly surged above $0.80, gaining over 25% in 24 hours following Multicoin Capital's investment. The DePIN project incentivizes users to share unused internet bandwidth, which is then used to process web data for AI labs. Grass plans to...
A wallet linked to Quant's founder transferred 25,776 QNT tokens valued at about $6.97 million after seven years of inactivity. The tokens were sent to several newly created wallets, while the original wallet still holds around 600,000 QNT tokens wor...
A wallet linked to Quant Network's founder moved 25,776 QNT tokens valued at $6.97 million after seven years of inactivity. The wallet still holds 600,000 QNT tokens worth $160.39 million. This transfer is significant in dollar terms but involves onl...
Concentrix Corporation reported mixed Q3 2026 results with earnings per share of $2.92, beating analyst expectations of $2.71. However, its revenue of $2.45 billion slightly missed the forecast of $2.48 billion. The company achieved a record free cas...
